Posttranslational regulation of Myc function in response to phorbol ester/interferon-γ-induced differentiation of v-Myc-transformed U-937 monoblasts

Blood

Volumn 93, Issue 11, 1999, Pages 3900-3912

  Bahram, Fuad ^a   Wu, Siqin ^a   Öberg, Fredrik ^a   Lüscher, Bernhard ^a   Larsson, Lars Gunnar ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PHORBOL ESTER;

ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; TRANSLATION REGULATION;

EID: 0033153098     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.11.3900.411a42_3900_3912     Document Type: Article

References (62)

1. Henriksson M, Lüscher B: Proteins of the Myc network: Essential regulators of cell growth and differentiation. Adv Cancer Res 68:109, 1996
2. Marcu KB, Bossone SA, Patel AJ: myc function and regulation. Annu Rev Biochem 61:809, 1992
3. Blackwood EM, Eisenman RN: Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251:1211, 1991
4. Prendergast GC, Lawe D, Ziff EB: Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell 65:395, 1991
5. Blackwood EM, Lüscher B, Eisenman RN: Myc and Max associate in vivo. Genes Dev 6:71, 1992
6. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H: Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 359:423, 1992
7. Kretzner L, Blackwood EM, Eisenman RN: Myc and Max proteins possess distinct transcriptional activities. Nature 359:426, 1992
8. Prendergast GC, Hopewell R, Gorham BJ, Ziff EB: Biphasic effect of Max on Myc cotransformation activity and dependence on amino- and carboxy-terminal Max functions. Genes Dev 6:2429, 1992
9. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H: Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72:233, 1993
10. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H: Sequence-specific DNA binding by the c-Myc protein. Science 250:1149, 1990
11. Kerkhoff E, Bister K, Klempnauer KH: Sequence-specific DNA binding by Myc proteins. Proc Natl Acad Sci USA 88:4323, 1991
12. Prendergast GC, Ziff EB: Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 251:186, 1991
13. Kato GJ, Barrett J, Villa-Garcia M, Dang CV: An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 10:5914, 1990
14. Amin C, Wagner AJ, Hay N: Sequence-specific transcriptional activation by Myc and repression by Max. Mol Cell Biol 13:383, 1993
15. Gu W, Cechova K, Tassi V, Dalla-Favera R: Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. Proc Natl Acad Sci USA 90:2935, 1993
16. Grandori C, Eisenman RN: Myc target genes. Trends Biochem Sci 22:177-81, 1997
17. Ayer DE, Kretzner L, Eisenman RN: Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72:211, 1993
18. Zervos AS, Gyuris J, Brent R: Mxil, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72:223, 1993
19. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN: Mad3 and Mad4: Novel Max-interacting transcriptional repressers that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. Embo J 14:5646, 1995
20. Hurlin PJ, Queva C, Eisenman RN: Mnt, a novel Maxinteracting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev 11:44, 1997
21. Meroni G, Reymond A, Alcalay M, Borsani G, Tanigami A, Tonlorenzi R, Nigro CL, Messali S, Zollo M, Ledbetler DH, Brent R, Ballabio A, Carrozzo R: Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor. EMBO J 16:2892, 1997
22. Cerni C, Bousset K, Seelos C, Burkhardt H, Henriksson M, Lüscher B: Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. Oncogene 11:587, 1995
23. Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho RA, Nisen PD: Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Nat Med 1:638, 1995
24. Roussel MF, Ashmun RA, Sherr CJ, Eisenman RN, Ayer DE: Inhibition of cell proliferation by the Madl transcriptional repressor. Mol Cell Biol 16:2796, 1996
25. Lahoz EG, Xu L, Schreiber-Agus N, DePinho RA: Suppression of Myc, but not Ela, transformation activity by Max-associated proteins, Mad and Mxil. Proc Natl Acad Sci USA 91:5503, 1994
26. Chin L, Schreiber-Agus N, Pellicer I, Chen K, Lee HW, Dudast M, Cordon-Cardo C, DePinho RA: Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci USA 92:8488, 1995
27. Koskinen PJ, Ayer DE, Eisenman RN: Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions. Cell Growth Differ 6:623, 1995
28. Västrik I, Kaipainen A, Penttila TL, Lymboussakis A, Alitalo R, Parvinen M, Alitalo K: Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro. J Cell Biol 128:1197, 1995
29. Kiermaier A, Eilers M: Transcriptional control: calling in histone deacetylase. Curr Biol 7:R505, 1997
30. Ayer DE, Eisenman RN: A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev 7:2110, 1993
31. Larsson LG, Pettersson M, Öberg F, Nilsson K, Lüscher B: Expression of mad, mxil, max and c-myc during induced differentiation of hematopoietic cells: Opposite regulation of mad and c-myc. Oncogene 9:1247, 1994
32. Hurlin PJ, Foley KP, Ayer DE, Eisenman RN, Hanahan D, Arbeit JM: Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene 11:2487, 1995
33. Larsson LG, Bahram F, Burkhardt H, Lüscher B: Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells. Oncogene 15:737, 1997
34. Queva C, Hurlin PJ, Foley KP, Eisenman RN: Sequential expression of the MAD family of transcriptional repressers during differentiation and development. Oncogene 16:967, 1998
35. Cultraro CM, BinoT, Segal S: Function of the c-Myc antagonist Mad 1 during a molecular switch from proliferation to differentiation. Mol Cell Biol 17:2353, 1997
36. Foley KP, McArthur GA, Queva C, Hurlin PJ, Soriano P, Eisenman RN: Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. EMBO J 17:774, 1998
37. Schreiber-Agus N, Meng Y, Hoang T, Hou H Jr, Chen K, Greenberg R, Cordon-Cardo C, Lee HW, DePinho RA: Role of Mxi1 in aging organ systems and the regulation of normal and neoplastic growth. Nature 393:483, 1998
38. Hunter T, Karin M: The regulation of transcription by phosphorylation. Cell 70:375, 1992
39. Öberg F, Larsson LG, Anton R, Nilsson K: Interferon gamma abrogates the differentiation block in v-myc-expressing U-937 monoblasts. Proc Natl Acad Sci USA 88:5567, 1991
40. Sundström C, Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17:565. 1976
41. Hihara H, Shimizu T, Yamamoto H: Establishment of tumor cell lines cultured from chickens with avian lymphoid leukosis. Natl Inst Anim Health Q Tokyo 14:163, 1974
42. Larsson LG, Ivhed I, Gidlund M, Pettersson U, Vennström B, Nilsson K: Phorbol ester-induced terminal differentiation is inhibited in human U-937 monoblastic cells expressing a v-myc oncogene. Proc Natl Acad Sci USA 85:2638, 1988
43. Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, AEG von dem Borne: Leukocyte Typing IV. Oxford, UK, University Press, 1989
44. Desbarats L, Gaubatz S, Eilers M: Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc. Genes Dev 10:447, 1996
45. Bousset K, Oelgeschlager MH, Henriksson M, Schreek S, Burkhardt H, Litchfield DW, Lüscher-Firzlaff JM, Lüscher B: Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II. Cell Mol Biol Res 40:501, 1994
46. Nilsson E, Lendahl U: Transient expression of a human beta-actin promoter/lacZ gene introduced into mouse embryos correlates with a low degree of methylation. Mol Reprod Dev 34:149, 1993
47. Gaubatz S, Meichle A, Eilers M: An E-box element localized in the first intron mediates regulation of the prothymosin alpha gene by c-myc. Mol Cell Biol 14:3853, 1994
48. Coppola JA, Cole MD: Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature 320:760, 1986
49. Dmitrovsky E, Kuehl WM, Hollis GF, Kirsch IR, Bender TP, Segal S: Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature 322:748, 1986
50. Prochownik EV, Kukowska J: Deregulated expression of c-myc by marine erythroleukaemia cells prevents differentiation. Nature 322:848, 1986
51. Freytag SO: Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1. Mol Cell Biol 8:1614, 1988
52. Hoffman-Liebermann B, Liebermann DA: Interleukin-6- and leukemia inhibitory factor-induced terminal differentiation of myeloid leukemia cells is blocked at an intermediate stage by constitutive c-myc. Mol Cell Biol 11:2375, 1991
53. Miner JH, Wold BJ: c-myc inhibition of MyoD and myogenininitiated myogenic differentiation. Mol Cell Biol 11:2842, 1991
54. Lüscher B, Kuenzel EA, Krebs EG, Eisenman RN: Myc oncoproteins are phosphorylated by casein kinase II. EMBO J 8:1111, 1989
55. Berberich SJ, Cole MD: Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. Genes Dev 6:166, 1992
56. Bousset K, Henriksson M, Lüscher-Firzlaff JM, Litchfield DW, Lüscher B: Identification of casein kinase II phosphorylation sites in Max: Effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers. Oncogene 8:3211, 1993
57. Ramsay G, Graf T, Hayman MJ: Mutants of avian myelocytomatosis virus with smaller gag gene-related proteins have an altered transforming ability. Nature 288:170, 1980
58. Alvarez E, Northwood IC, Gonzalez FA, Latour DA, Seth A, Abate C, Curran T, Davis RJ: Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase. J Biol Chem 266:15277, 1991
59. Henriksson M, Bakardjiev A, Klein G, Lüscher B: Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 8:3199, 1993
60. Lutterbach B, Hann SR: Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14:5510, 1994
61. Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR: Site-specific modulation of c-Myc cotransfotmation by residues phosphorylated in vivo. Oncogene 9:59, 1994
62. Hoang AT, Lutterbach B, Lewis BC, Yano T, Chou TY, Barrett JF, Raffeld M, Hann SR, Dang CV: A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol 15:4031, 1995